129 related articles for article (PubMed ID: 7296877)
1. Assay of fumarylacetoacetate fumarylhydrolase in human liver-deficient activity in a case of hereditary tyrosinemia.
Kvittingen EA; Jellum E; Stokke O
Clin Chim Acta; 1981 Sep; 115(3):311-9. PubMed ID: 7296877
[TBL] [Abstract][Full Text] [Related]
2. Deficiency of fumarylacetoacetase in a patient with hereditary tyrosinemia.
Berger R; Smit GP; Stoker-de Vries SA; Duran M; Ketting D; Wadman SK
Clin Chim Acta; 1981 Jul; 114(1):37-44. PubMed ID: 7249373
[TBL] [Abstract][Full Text] [Related]
3. Enzyme defect in a case of tyrosinemia type I, acute form.
Furukawa N; Kinugasa A; Seo T; Ishii T; Ota T; Machida Y; Inoue F; Imashuku S; Kusunoki T; Takamatsu T
Pediatr Res; 1984 May; 18(5):463-6. PubMed ID: 6145143
[TBL] [Abstract][Full Text] [Related]
4. Deficient fumarylacetoacetate fumarylhydrolase activity in lymphocytes and fibroblasts from patients with hereditary tyrosinemia.
Kvittingen EA; Halvorsen S; Jellum E
Pediatr Res; 1983 Jul; 17(7):541-4. PubMed ID: 6622096
[TBL] [Abstract][Full Text] [Related]
5. Localization of fumarylacetoacetate fumarylhydrolase in rat liver.
Doshi KS; Schmidt DE
Can J Biochem; 1978 Sep; 56(9):866-8. PubMed ID: 728842
[TBL] [Abstract][Full Text] [Related]
6. Urinary excretion of succinylacetone and delta-aminolevulinic acid in patients with hereditary tyrosinemia.
Christensen E; Jacobsen BB; Gregersen N; Hjeds H; Pedersen JB; Brandt NJ; Baekmark UB
Clin Chim Acta; 1981 Nov; 116(3):331-41. PubMed ID: 7296896
[TBL] [Abstract][Full Text] [Related]
7. On the enzymic defects in hereditary tyrosinemia.
Lindblad B; Lindstedt S; Steen G
Proc Natl Acad Sci U S A; 1977 Oct; 74(10):4641-5. PubMed ID: 270706
[TBL] [Abstract][Full Text] [Related]
8. Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I).
Tanguay RM; Valet JP; Lescault A; Duband JL; Laberge C; Lettre F; Plante M
Am J Hum Genet; 1990 Aug; 47(2):308-16. PubMed ID: 2378356
[TBL] [Abstract][Full Text] [Related]
9. Biochemical studies on the enzymatic deficiencies in hereditary tyrosinemia.
Berger R; van Faassen H; Smith GP
Clin Chim Acta; 1983 Oct; 134(1-2):129-41. PubMed ID: 6652907
[TBL] [Abstract][Full Text] [Related]
10. Localization of cells in the rat brain expressing fumarylacetoacetate hydrolase, the deficient enzyme in hereditary tyrosinemia type 1.
Labelle Y; Puymirat J; Tanguay RM
Biochim Biophys Acta; 1993 Jan; 1180(3):250-6. PubMed ID: 8422430
[TBL] [Abstract][Full Text] [Related]
11. Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I.
St-Louis M; Leclerc B; Laine J; Salo MK; Holmberg C; Tanguay RM
Hum Mol Genet; 1994 Jan; 3(1):69-72. PubMed ID: 8162054
[TBL] [Abstract][Full Text] [Related]
12. Hereditary tyrosinemia type I: lack of correlation between clinical findings and amount of immunoreactive fumarylacetoacetase protein.
Kvittingen EA; Rootwelt H; van Dam T; van Faassen H; Berger R
Pediatr Res; 1992 Jan; 31(1):43-6. PubMed ID: 1594329
[TBL] [Abstract][Full Text] [Related]
13. Acute hereditary tyrosinaemia type I: clinical, biochemical and haematological studies in twins.
Gray RG; Patrick AD; Preston FE; Whitfield MF
J Inherit Metab Dis; 1981; 4(1):37-40. PubMed ID: 6785523
[TBL] [Abstract][Full Text] [Related]
14. The effects of early treatment of hereditary tyrosinemia type I in infancy by orthotopic liver transplantation.
Flye MW; Riely CA; Hainline BE; Sassa S; Gusberg RJ; Blakemore KJ; Barwick KW; Horwich AL
Transplantation; 1990 May; 49(5):916-21. PubMed ID: 2336709
[TBL] [Abstract][Full Text] [Related]
15. The enzyme defects in hereditary tyrosinaemia type I.
Furukawa N; Hayano T; Sato N; Inoue F; Machida Y; Kinugasa A; Imashuku S; Kusunoki T; Takamatisu T
J Inherit Metab Dis; 1984; 7 Suppl 2():137-8. PubMed ID: 6434869
[No Abstract] [Full Text] [Related]
16. Purification of mRNA coding for the enzyme deficient in hereditary tyrosinemia, fumarylacetoacetate hydrolase.
Nicole LM; Valet JP; Laberge C; Tanguay RM
Biochem Cell Biol; 1986 May; 64(5):489-93. PubMed ID: 3718716
[TBL] [Abstract][Full Text] [Related]
17. Correction of fumarylacetoacetate hydrolase deficiency (type I tyrosinemia) in cultured human fibroblasts by retroviral-mediated gene transfer.
Phaneuf D; Hadchouel M; Tanguay RM; Bréchot C; Ferry N
Biochem Biophys Res Commun; 1995 Mar; 208(3):957-63. PubMed ID: 7702626
[TBL] [Abstract][Full Text] [Related]
18. Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes.
Poudrier J; Lettre F; Scriver CR; Larochelle J; Tanguay RM
Mol Genet Metab; 1998 Jun; 64(2):119-25. PubMed ID: 9705236
[TBL] [Abstract][Full Text] [Related]
19. Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect.
Kvittingen EA; Rootwelt H; Brandtzaeg P; Bergan A; Berger R
J Clin Invest; 1993 Apr; 91(4):1816-21. PubMed ID: 8473520
[TBL] [Abstract][Full Text] [Related]
20. Characterization and substrate specificity of fumarylacetoacetate fumarylhydrolase.
Mahuran DJ; Angus RH; Braun CV; Sim SS; Schmidt DE
Can J Biochem; 1977 Jan; 55(1):1-8. PubMed ID: 13916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
